| Title |
Onivyde for the therapy of multiple solid tumors
|
|---|---|
| Published in |
OncoTargets and therapy, May 2016
|
| DOI | 10.2147/ott.s105587 |
| Pubmed ID | |
| Authors |
Haijun Zhang |
| Abstract |
Drug delivery system based on nanobiotechnology can improve the pharmacokinetics and therapeutic index of chemotherapeutic agents, which has revolutionized tumor therapy. Onivyde, also known as MM-398 or PEP02, is a nanoliposomal formulation of irinotecan which has demonstrated encouraging anticancer activity across a broad range of malignancies, including pancreatic cancer, esophago-gastric cancer, and colorectal cancer. This up-to-date review not only focuses on the structure, pharmacokinetics, and pharmacogenetics of Onivyde but also summarizes clinical trials and recommends Onivyde for patients with advanced solid tumors. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 151 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 151 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 28 | 19% |
| Student > Master | 21 | 14% |
| Researcher | 18 | 12% |
| Student > Bachelor | 16 | 11% |
| Student > Doctoral Student | 8 | 5% |
| Other | 13 | 9% |
| Unknown | 47 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 26 | 17% |
| Biochemistry, Genetics and Molecular Biology | 20 | 13% |
| Chemistry | 14 | 9% |
| Agricultural and Biological Sciences | 10 | 7% |
| Medicine and Dentistry | 9 | 6% |
| Other | 18 | 12% |
| Unknown | 54 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2023.
All research outputs
#7,363,939
of 25,394,764 outputs
Outputs from OncoTargets and therapy
#377
of 3,016 outputs
Outputs of similar age
#97,712
of 311,961 outputs
Outputs of similar age from OncoTargets and therapy
#18
of 123 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,961 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 123 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.